Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
Location status: Recruiting
NCT Number: NCT07105436
Persistent air leaks (PALs) are a common postoperative complication resulting from tears in the visceral pleura or peripheral lung resections. Although highly prevalent with significant consequences, traditional assessment methods lack the capability to objectively quantify air leaks, which further complicates management, results in inconsistent decision making, and prolongs hospital stays. By incorporating the Thopaz+ system, the investigators can introduce a reliable approach to objectively quantify air leaks, potentially improving clinical outcomes.
The purpose of this protocol is to perform a pilot prospective controlled clinical trial to evaluate the utility of incorporating the Thopaz+ system and its volume quantification ability in evaluating patients with persistent air leaks (PALs) to guide treatment decisions, specifically endobronchial valves (EBVs).
In the targeted cohort, the Thopaz+ will be connected to the chest tube and the data collected will be combined with that of serial balloon occlusion testing with a Fogarty balloon to accurately localize the air leak source, and subsequently consider the correct placement of EBVs. The investigators will thereby determine whether this experimental strategy will yield a more accurate and objective assessment of air leaks, facilitating timely interventions and improved patient outcomes.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Boston, Massachusetts, 02215, United States
Location status: Recruiting
The investigators will conduct a prospective controlled clinical trial. The investigators' target demographic includes all adult patients with lung resection and/or non-lung resection-related PAL with ipsilateral chest tubes who were not candidates for surgical intervention or patients who refused the intervention. These patients would undergo a multidisciplinary review by thoracic surgery, interventional pulmonary and the primary care team to consider a bronchoscopic approach with endobronchial valves and possibly bronchial blood patch, which is currently considered standard of care at our institution. During this standard-of-care intervention, quantitative assessment of distal occluded airway pressures/flows in various airways, as well as quantitative assessment of air leak volume will be assessed.
In current medical practice, when EBVs are considered in the context of managing PALs, bronchoscopists may opt to either conduct complete lobar occlusion (sealing of all segments within the target lobe) or segmental occlusion (sealing only selected segments within the target lobe). The decision is usually guided by localizing the source of air leak which is usually done by monitoring the reduction of air leak on the pleural drainage device following serial inflation of a Fogarty Catheter at various locations within the endobronchial tree and monitoring change in air leak visually in the pleural drainage system.
In this trial, patients with PALs will have their chest tubes connected to the Thopaz+ system. The Thopaz+ will continuously quantify the volume of air leaks, providing real-time data for analysis.
Data from both the Thopaz+ and standard serial occlusion test with Fogarty balloon will be combined and integrated to provide a comprehensive assessment of the air leak source. The bronchoscopist will perform standard visual assessment of changes in air leak during serial balloon occlusion in order to identify the best region for endobronchial treatments; use of measurements from the Thopaz and serial balloon occlusion test will be allowed as part of clinical reasoning but are not required to be used by the treating clinician.
Continuous monitoring using the Thopaz+ system may continue post-procedure to track changes in air leak volumes and patient recovery, ensuring timely interventions and optimal patient outcomes. This integrated approach aims to provide a more accurate, objective, and efficient method of managing PALs compared to traditional techniques.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
In this trial, patients with PALs will have their chest tubes connected to the Thopaz+ system. The Thopaz+ will continuously quantify the volume of air leaks, providing real-time data for analysis.
Data from both the Thopaz+ and standard serial occlusion test with Fogarty balloon will be combined and integrated to provide a comprehensive assessment of the air leak source. The bronchoscopic will perform standard visual assessment of changes in air leak during serial balloon occlusion in order to identify the best region for endobronchial treatments; use of measurements from the Thopaz and serial balloon occlusion test will be allowed as part of clinical reasoning but are not required to be used by the treating clinician.
Time frame: During procedure
Feasibility will be defined by the ability to obtain continuous, interpretable quantitative air leak volume data (in mL/min) during bronchoscopic evaluation of persistent air leaks. Successful quantification is defined as capturing measurable air leak volume data during serial balloon occlusion in at least one airway segment. The outcome will be reported as the number and percentage of participants with successful measurements out of the total enrolled population.
Time frame: During procedure
Percentage of patients with identifiable lobar or segmental airways responsible for PAL
Time frame: During procedure
Time frame: From enrollment until 8 weeks follow-up (as per standard of care for bronchoscopic treatment of PALs)
The Cerfolio classification categorizes air leaks based on their occurrence during the respiratory cycle, with grades 1-4 indicating increasing severity. Grade 1 is a forced expiratory leak, seen during coughing; Grade 2, expiratory; Grade 3, inspiratory; and Grade 4, continuous during both inspiration and expiration
Time frame: From enrollment until 8 weeks follow-up (as per standard of care for bronchoscopic treatment of PALs)
Time frame: From enrollment until 8 weeks follow-up (as per standard of care for bronchoscopic treatment of PALs)
Time frame: From enrollment until 8 weeks follow-up (as per standard of care for bronchoscopic treatment of PALs)
Time frame: From enrollment until 8 weeks follow-up (as per standard of care for bronchoscopic treatment of PALs)
The Cerfolio classification categorizes air leaks based on their occurrence during the respiratory cycle, with grades 1-4 indicating increasing severity. Grade 1 is a forced expiratory leak, seen during coughing; Grade 2, expiratory; Grade 3, inspiratory; and Grade 4, continuous during both inspiration and expiration
Time frame: From enrollment until 8 weeks follow-up (as per standard of care for bronchoscopic treatment of PALs)
The Thopaz+ device will be used to continuously measure the volume of air leak (in mL/min) before and after bronchoscopic intervention. The outcome will report the change in air leak volume from baseline (pre-bronchoscopy) to post-bronchoscopy values.
Time frame: From enrollment until 8 weeks follow-up (as per standard of care for bronchoscopic treatment of PALs)
Time frame: From enrollment until 8 weeks follow-up (as per standard of care for bronchoscopic treatment of PALs)
Contact information is provided by the study sponsor or research team.
Kai Swenson
Other
Utility of the Thopaz+ System in Evaluating Persistent Air Leaks
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07184528
Persistent Air Leaks
Boston, Massachusetts, United States
View Trial Details